Education
About Us
Working with TipRanks
Follow Us
Cytokinetics (CH:KK3A)
:KK3A
KK3A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
---
Bulls Say, Bears Say
Bulls Say
Analyst ConfidenceAnalyst maintains a Buy rating for CYTK stocks, indicating confidence in the company's future performance.
Financial StabilityCytokinetics finished the first quarter with approximately $1.1 billion in cash and cash equivalents, providing financial runway beyond aficamten's potential US launch.
Regulatory ConfidenceManagement remains confident in aficamten's benefit-risk profile and differentiated positioning upon potential approval.
Bears Say
Commercial Launch RisksThere are uncertainties over Cytokinetics' ability to execute a successful commercial launch due to its lack of experience and commercial footprint.
Regulatory DelaysThe FDA's decision to delay aficamten's PDUFA has left more questions than answers, affecting investor confidence.
Revenue ForecastRevenue forecast for aficamten in the US and EU was lowered by 12% and 35%, respectively, due to rising competition in HCM drug development.
---
KK3A FAQ
What was Cytokinetics’s price range in the past 12 months?
Currently, no data Available
What is Cytokinetics’s market cap?
Currently, no data Available
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Jul 31, 2025 which is in 74 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on May 06, 2025. The company reported -$1.147 earnings per share for the quarter, beating the consensus estimate of -$1.155 by $0.008.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.2.
How many shares outstanding does Cytokinetics have?
Currently, no data Available
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -$1.147 in its last earnings report, beating expectations of -$1.155. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CH:KK3A
---
Cytokinetics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.11 (― Downside)
$64.11 (― Downside)
Blogger Sentiment
Bullish
CH:KK3A Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $9.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-48.26%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.43%
Trailing 12-Months
Company Description
Cytokinetics
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
---
KK3A Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of positive developments, such as early trial enrollment completion and strong financial positioning, countered by delays in drug approval and increased expenses. The sentiment is balanced with notable achievements and challenges.Read More>---
KK3A Stock 12 Month Forecast
Average Price Target
$64.11
---